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Electroretinographic modifications induced by 
agomelatine: a novel avenue to the understanding 
of the claimed antidepressant effect of the drug?
Background: Agomelatine, the first melatonergic antidepressant, has been  postulated to 
enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine 
receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway 
is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the 
central nervous system dopaminergic activity, namely the standard electroretinogram (ERG) 
technique, suggested a reduction of the dopaminergic activity of the main ERG parameter, the 
b-wave, by pure melatonin, notably a hormone devoid of any antidepressant activity. Therefore, 
the antidepressant effects of the melatonergic antidepressant drug agomelatine should be reflected 
by a differential b-wave trend at ERG versus the effect exerted by pure melatonin, which was 
eventually found to be due to a contrasting effect on central dopaminergic transmission between 
the two drugs.
Objective and methods: The aim of the present preliminary ERG study carried out on healthy 
volunteers (n=23) receiving agomelatine was to explore the impact of this antidepressant drug 
on b-wave amplitude and latency of cones in daylight conditions using standard ERG.
Results: As postulated, agomelatine induced an enhancement of retinal dopaminergic activity, 
in contrast to what has been previously documented for melatonin.
Conclusion: Given the limits of this explorative study, especially the lack of a control group 
and that of a luminance response function to measure retinal sensitivity, further studies in clinical 
samples are recommended to allow more tenable conclusions about the potential role of ERG 
in discriminating between 5-HT antagonism and melatonergic (MT) agonism in relationship 
to the claimed antidepressant effect of agomelatine.
Keywords: electroretinogram, ERG, dopamine, 5-HT2C
Introduction
Currently, virtually any psychiatric diagnosis is made through a combination of 
patient interviews, checklists, or self-report questionnaires, which rely on the symp-
toms coded in the Diagnostic and Statistical Manual of Mental Disorders, either 
the fourth  edition1 or the recently introduced fifth edition.2 Yet, considerable debate 
exists about the actual validity of this sole symptom-based approach, thus sustain-
ing the interest in objective biomarkers toward a better understanding of psychiatric 
disorders, including major depressive disorder (MDD), and their pharmacological 
response.3 Furthermore, a number of issues, including heterogeneous patients’ 
variables, high medical and psychiatric comorbidity rates, medications/triggers, 
inconsistency in specimen collection, storage and measurement protocols, and 
complexity of neuropsychiatric biological determinants of disorders, hinder the 
search for reliable biomarkers.4,5  Ideally, a hassle-free biomarker reflecting the 





central nervous system (CNS) functioning should provide 
a simplified, yet reliable, proxy measure of the  activity of 
those neurotransmitters that are supposed to be involved in 
major psychiatric  disturbances, to be flexibly applied both to 
clinical and healthy samples. Among other approaches, the 
electroretinogram (ERG) represents a relatively noninvasive, 
short, and cost-effective method developed to investigate 
the origin of a visual loss due to a retinal disease or injury, 
possibly representing a proxy of global CNS activity of 
dopamine,6 a core monoamine in depression, directly or 
indirectly modulated by a number of antidepressant drugs 
with different pharmacodynamics.7 Specifically, since the 
retina is part of the CNS due to its embryonic origin, the 
ERG has been used to investigate not only MDD, but also 
seasonal affective disorder, schizophrenia and bipolar disor-
der, autism spectrum disorders, and drug addiction,8 both in 
clinical and healthy samples exposed to different pharmaco-
logical agents,8–17 as well as in animal samples.6,18 Of note, 
dopamine modulates different retinal functions, including 
counterbalancing of the synthesis of melatonin as mea-
sured with the ERG.19–21 Melatonergic activity is also often 
impaired in the course of depressive episodes with prominent 
circadian rhythm disturbances, even if there is no antidepres-
sant effect firmly documented for the hormone melatonin, 
neither for its analogue, ramelteon.22–25 This seems quite 
puzzling considering that the recently released pro-mela-
tonergic antidepressant agomelatine has been approved in 
Europe for the treatment of MDD, though not in the US.26,27 
A potential explanation for the claimed antidepressant 
effect of agomelatine should nonetheless be represented 
by its 5-hydroxytryptamine receptor type 2B (5-HT2B) 
and 5-HT2C serotonergic antagonism,28 which may also 
promote the dopaminergic firing at the ventral tegmental 
area, frontal cortex, hypothalamus, hippocampus, medulla 
and pons, and also the retina, which is part of the CNS as 
well,29 via enhancement of norepinephrinergic activity at 
the locus coeruleus.30 Yet, while there is no question about 
the impact of melatonergic modulation on circadian rhythms 
relevant for mood as well as other core functions, the dis-
crimination of the most plausible antidepressant effect of 
agomelatine between 5-HT antagonism versus melaton-
ergic receptor type 1 (MT1) and type 2 (MT2) agonism 
remains elusive, at least with regard to just the simplified 
paradigm of dopaminergic modulation. Additionally, ago-
melatine has been proposed to indirectly modulate even the 
release of glutamate from prefrontal and frontal cortex and 
hippocampus,31,32 which further hinders the identification of 
a sole putative neurobiological pathway accounting for the 
claimed antidepressant effect of the drug.
Therefore, the aim of this preliminary study carried out on 
healthy volunteers was to assess the impact of agomelatine on 
retinal dopaminergic activity measured using standard ERG 
recording, to provide a dissertation on the potential clinical 
implications of a differential neuropsychopharmacological 
ERG trend eventually observed for agomelatine versus the 
trend already documented for melatonin.
Methods
The flash ERG: essential 
neuropsychopharmacological foundations
The light reaches the photoreceptors (either cones or rods) 
hosted at the outer segment of the retina after crossing the ante-
rior segment of the eye, then is absorbed by the photopigment 
of the photoreceptors, which ignites the phototransduction 
process. In dark conditions, photoreceptors rest in a depolarized 
state, while the photon absorption leads to their hyperpolariza-
tion followed by the depolarization of the ON bipolar cells. 
Subsequently, the electric signal spreads to the ganglion cells, 
the axons of which reach the brain, mainly converging at the 
visual cortex. The retina also includes horizontal cells and 
amacrine cells, which are interneurons joining photoreceptors 
and bipolar cells, as well as the Müller cells acting as glia.8
Since dopamine represents a core retinal neurotransmitter 
involved in signal transduction, the ERG should be a conve-
nient technique by which to assess such dopaminergic activity 
both in light- and dark-adapted conditions,33 essentially by 
measurement of the “implicit time” and “amplitude” para-
meters of the b-wave,34 a trace component of the ERG pri-
marily determined by the bipolar cells.35–37 Any variation of 
the intensity or chromatic characteristic of the light stimulus 
could also be assessed by the ERG, either for rods, cones, or 
mixed rod/cone photoreceptors functioning, thus allowing 
an objective quantitative measure of the retinal sensitivity 
to light.34 Dopamine released by the amacrine and inter-
plexiform cells38 interacts with the D1-like receptors (namely, 
D1 and D5 subtypes) at the horizontal, bipolar, amacrine, and 
ganglion cells, and with the D2-like (D2, D3, and D4) recep-
tors located at the retinal pigment epithelium cells, photore-
ceptors, and Müller glial cells,39–43 all of which are involved 
in the modulation of a number of retinal functions, including 
melatonin release.20 Also, the daily synthesis and release of 
retinal dopamine, which is primarily influenced by lighting 
condition, follows a 24-hour rhythm,44 being influenced by 
the interaction between the amacrine and interplexiform 
dopaminergic neurons and photoreceptors. Enhancement 
of dopamine activity via activation of D2-like receptors 
(namely D4 ones) located on photoreceptors inhibits the 
synthesis of melatonin, leading to subsequent inhibition of 





serotonergic N-acetyltransferase activity.45,46 In mammals, 
the D4 receptor accounts for the effects of the ligands on the 
whole D2 receptor family,42 either at the rods, cones, or retinal 
pigment epithelium,47 which, in turn, ultimately account for 
the impact of dopamine in the regulation of melatonin bio-
synthesis in vertebrate retina.48 Substance P and dynorphin, 
which are expressed in D1 receptor-containing neurons, as 
well as preproenkephalin in D2 receptor-containing neurons, 
have also been used as monitors of dopaminergic activity 
in the CNS,49 whereas there have been conflicting reports 
as to whether D1-like receptors are capable of increas-
ing or decreasing the potassium efflux: D1-like agonists 
increase potassium current from chick retinal cells via an 
adenosine monophosphate (AMP)-independent mechanism, 
but inhibit this efflux in rat striatal neurons;50 as such, a 
conclusive understanding of the actual effect of D1 (and 
possibly D5) stimulation or inhibition at the retina likewise 
remains elusive.51 Melatonin suppresses the retinal release 
of dopamine via activation of its own melatonergic receptors 
(primarily MT1, but also MT2 and MT3 subtypes), widely 
distributed in the CNS,52 including the retinal amacrine and 
interplexiform dopaminergic neurons.53,54
As mentioned previously, the b-wave response of the 
ERG is influenced both by dopaminergic and melatonergic 
modulation. Specifically, in daylight conditions, the b-wave 
response seems linked to cone dominance, possibly related 
to a shift toward a relative dominance of dopaminergic tone. 
On the contrary, under scotopic conditions, the b-wave 
response could be influenced by a relative dominance of 
rod tone,55 when the presence of circulating melatonin could 
account for rod dominance.56
ERG studies carried out on healthy volunteers receiving 
melatonin, performed during conditions usually characterized 
by the absence of the hormone itself, showed a decline of cone 
response, either recorded as a decrease of the b-wave ampli-
tude at 10 mg/day,57 or as a significant reduction of cones’ 
ERG maximal response associated to a prolonged implicit 
time with 15 mg/day melatonin.58 Concordant results were 
recently documented in animal samples exposed to high doses 
of melatonin during the day (90 mg/day in anaesthetized 
beagle dogs), showing a decrease of the photopic amplitude 
of both a- and b-waves, but no impact on the implicit time, 
which may indicate that the negative impact of melatonin on 
the photopic system may promote night vision.21
Agomelatine shares the MT1 and MT2 agonism provided 
by melatonin, but not the agonism on MT3 receptors, with 
MT3 receptors having not been documented in mammalian 
samples.59 By blocking 5-HT2C receptors, agomelatine pro-
motes the CNS release of dopamine, possibly at the retina as 
well. However, at the time of writing, there are no available 
data whatsoever about the investigation of agomelatine using 
the flash ERG in contrast to previous evidence for melatonin, 
this being the aim of this preliminary study.
study subjects
Twenty-three healthy volunteers, both sexes, were enrolled at 
the Department of Neuroscience of the San Martino  Hospital 
of Genoa, Genoa, Italy, between September 2012 and 
March 2013, upon approval by the local ethical committee 
and patient signatures on a valid informed consent form after 
procedures had been fully explained by the investigators 
(either psychiatrists or neurologists). All procedures were 
carried out in accordance with the Declaration of Helsinki 
about human experimentation.60 No liver function monitor-
ing was needed due to the prescription of just a single dose 
of agomelatine. In order to avoid any age-dependent effect 
affecting the b-wave amplitude,61 all subjects were aged 
between 22 and 35 years old. In addition, all subjects received 
the same single dose of agomelatine (25 mg/day), avoiding 
any concomitant medication to limit potential confounding 
biases as much as possible. Similar considerations led to the 
inclusion of female subjects only during the luteal phase of 
the menstrual cycle (objective measure of luteinizing hor-
mone levels: range 1–20 IU/L) in order to avoid an addi-
tional confounding factor potentially affecting the b-wave 
 amplitude.62 Finally, the baseline ERG assessments (with 
each session requiring about 1 hour for completion) were 
performed according to the following scheme: 1) first ERG 
recording at 10 am (baseline =T0), immediately followed 
by oral intake of agomelatine 25 mg (one pill); 2) 1 hour’s 
rest; 3) second ERG recording; 4) 1 (more) hour’s rest; 5) 
third (final) ERG measurement. Finally, a pictorial descrip-
tion of the standard ERG has been provided in Figure 1 along 











Figure 1 The a-wave of the electroretinogram reflects the activity of photoreceptors; 
the b-wave indicates the activity of the amacrine, horizontal, bipolar, and Müller 
cells. implicit time refers to the time occurring between the initiation of the light 
stimulation (flash) and the peak of a- and b-waves. The a-wave amplitude was 
measured from baseline to a-wave trough; the b-wave amplitude was measured 
from a-wave trough to b-wave peak.





Enrolled healthy volunteers received their oral prescription of 25 mg
 agomelatine (one pill) just following their first ERG assessment (which 
usually took about 1 hour, each session).
First ERG assessment (baseline)
Second ERG assessment (T1) 
After 1 hour rest (around noon), the study participants underwent their 
second ERG session. At this time, about 60 minutes had lapsed since 
baseline, plus the time needed to complete each ERG session.
Last ERG assessment (T2)
After 1 additional hour rest (around 2 pm), patients underwent their last
ERG session. At this time, about 120 minutes had lapsed since baseline,
plus the time needed to complete each ERG session.
Figure 2 Flowchart of study procedures.
Abbreviation: erg, electroretinogram.
stimulation and recording
All subjects underwent a full-field ERG recording. The 
 electric signal was recorded binocularly (dilated pupils) 
using 9 mm silver/silver chloride skin disc electrodes placed 
on the lower eyelid; the reference electrodes were placed 
close to the outer canthus of the eye and the ground electrode 
was placed on the forehead. The electrode impedance was 
maintained below 5 kΩ in order to provide consistent results 
independent of the response yielded by skin electrodes with 
lower amplitude and higher noise levels with regard to either 
the corneal or conjunctival electrodes. The band-pass filter 
was set between 0.1 Hz and 500 Hz, and the subjects were 
dark-adapted for 20 minutes before recording. A full-field 
Ganzfeld stimulator was used throughout the study, with 
the subjects seated in front of the stimulator bowl fixating 
on a point incorporated in the stimulus dome during each 
session. The dark-adapted 0.01 ERG (rod response) was 
recorded using a dim white flash of 0.01 cdsm2. The dark-
adapted 3.0 ERG (combined rod–cone response) was gen-
erated by a white 3 cdsm2 flash. After 10 minutes of light 





adaptation, the light-adapted 3.0 ERG (single-flash cone 
response) was recorded, using a 3 cdsm2 stimulus with a back-
ground luminance of 30 cd/m2 measured at the surface of the 
full-field stimulus bowl. b-wave amplitude and time to peak 
(implicit time) were measured (ms) for all ERGs. The a-wave 
was measured when detectable. The a-wave amplitude was 
measured from baseline to a-wave trough, while the b-wave 
amplitude was measured from a-wave trough to b-wave peak 
(µV); the a-wave and b-wave implicit times were measured 
from the time of the flash to the peak of each wave.
statistical analysis
Demographic and descriptive analyses were carried out using 
the IBM SPSS® software package (v 21) for Microsoft Win-
dows® (v 7) (IBM Corporation, Armonk, NY, USA). Since 
data follow a nonparametric distribution, as assessed by the 
Shapiro–Wilk test, Friedman’s analysis of variance was used in 
order to compare the median scores of the ERG parameters.
Results
Twenty-three subjects (females n=8 or 35% of the sample; 
males n=15 or 65%) were included in the study and com-
pleted all the scheduled appointments and procedures. The 
average age was 26.61±3.3 years. Notably, among different 
measures of the b-wave parameters for both eyes (including 
latency and amplitude either for cones or rods, and for ERG 
maximal response), the only statistically significant modifica-
tions observed across the study were those related to cones’ 
b-wave amplitude and latency, in both eyes (Table 1). Finally, 
no statistically significant difference was observed for such 
parameters in males versus females.
Discussion
limitations of the study
The absence of a control group, including differential 
doses of agomelatine, placebo, or melatonin, or depressed 
controls, make the present results merely indicative at this 
time. Moreover, while dopamine could also affect the ERG, 
its effect was basically observed in terms of changes in the 
retinal sensitivity.63 Therefore, in this study, the lack of a 
luminance response function to measure retinal sensitivity 
with the ERG prompts for caution in the interpretation of 
our preliminary findings. Oscillatory potentials most likely 
generated by the dopaminergic neurons of the amacrine 
(or interplexiform) cells, should also be accounted for in 
replication studies. Similarly, we followed the International 
Society for Clinical Electrophysiology of Vision (ISCEV) 
Standard64 to record the ERG, which represents the minimum 
standard flashes to be used to investigate the retinal function 
(for patients with an eye disease); however, in terms of mere 
research purposes, assessing the dynamic of retinal function-
ing over a wide range of intensities should allow a more 
reliable assessment of the retinal sensitivity. Specifically, 
this latter consideration may have hampered the validity of 
the present preliminary protocol in the investigation of a 
possible impact of the ERG.
clinical and neuropsychopharmacological 
implications of study results
In our sample, agomelatine induced a slight, yet statistically sig-
nificant, increase of the cones’ b-wave amplitude and latency 
in both eyes. While it may be argued that the above mentioned 
change in amplitude may actually be within the normal 
variation of the measure, this is nonetheless in contrast to 
previous reports56–58 from comparable ERG studies involving 
healthy subjects receiving melatonin. While both melatonin 
and agomelatine act on melatonergic receptors, the presence 
of 5-HT2C (and 5-HT2B) antagonism for the antidepressant 
drug should be prudently hypothesized to account for the 
differential trend observed at ERG, eventually observed to 
play a role in the therapeutic effect claimed in depressed 
samples. Notably, a previous polysomnographic study 
Table 1 Slightly, yet statistically, significant trends of increase of b-wave parameters
LE RE
Baseline value 60 minutes 120 minutes Baseline value 60 minutes 120 minutes
amplitude of the cones ± sD
(le P=0.026;
re P=0.009)*
49.22±18.71 52.30±18.43 55.52±20.95 45.35±18.48 48.65±17.02 51.56±17.22
cone latency ± sD
(le P=0.001;
re P=0.001)*
33.83±2.79 34.74±3.67 36.39±3.13 33.52±2.69 34.48±3.33 36.17±3.08
Notes: Modifications that were not statistically significant are omitted (Friedman’s two-way analysis of variance by ranks). REs and LEs were analyzed separately. Amplitude 
values are in µV (latency in ms). All results were obtained in daylight conditions. *Provided P-values for the nonparametric test indicated to reject the null hypothesis 
(of a difference observed by chance); asymptotic significance not reported; significance level set to P=0.05.
Abbreviations: le, left eye; re, right eye; sD, standard deviation.





carried out on a small sample of healthy volunteers with 
the same dose of agomelatine (25 mg/day) raised doubts 
about the actual blockade of 5-HT2C receptors in humans, 
based on the observation that this agent failed to increase 
slow-wave sleep, whereas potent 5-HT2C antagonists 
(eg, cyproheptadine 4 mg, ritanserin 5 mg, olanzapine 5 mg, 
or mirtazapine 30 mg) did.65 Furthermore, in a recent animal 
study, neither the long-term administration of melatonin 
(40 mg/kg/day) nor the selective 5-HT2C receptor antagonist 
SB 242084 (0.5 mg/kg/day) had an effect on the firing rate 
and burst parameters of serotonergic and dopaminergic neu-
rons. The combination of these latter mechanisms, however, 
enhanced only the number of spontaneously active dopamin-
ergic neurons at the ventral tegmental area, while leaving the 
firing of the serotonergic neurons unaltered at the raphe dorsal 
nucleus. Finally, the addition of a specific 5-HT2B antagonist 
(LY 266097 at 0.6 mg/kg/day), which proved by itself to be 
devoid of effect, to the previous dual regimen increased the 
number of bursts per minute of dopaminergic neurons and 
the percentage of spikes occurring in burst, which ultimately 
mimics the effect of the antidepressant agomelatine.66
Conclusion
Agomelatine may differ from  melatonin not only in the 
absence of MT3 agonism, but also in the presence of a dual 
antagonism on 5-HT2C and 5-HT2B, which may  corroborate 
the claimed clinical antidepressant effect and account for 
the increase of the b-wave amplitude and latency of the 
cones (in daylight conditions). Nonetheless, along with the 
abovementioned limitations urging much prudence in 
the interpretation of our results and the acknowledgement 
that a decline in the central serotonin activity may itself 
affect the cone b-wave latency, it pays to note that the 
“ classical” paradigm of monoamines (including dopamine) 
as a core pathway involved in depression has been debated, 
 shifting more attention toward impaired circadian rhythms in 
 depression.67 Therefore, with the ultimate goal of shedding 
further light on the mechanism of action of novel antidepres-
sants, with agomelatine being the case in point, additional, 
more methodologically accurate ERG studies on the matter 
are warranted.
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